CDK4 and breast carcinoma: Therefore, biomarkers are urgently needed to predict CDK4/6 inhibitor efficacy or resistance in metastatic breast cancer patients, allowing clinicians to tailor treatment and potentially add additional therapies for patients at high risk of early progression.